Nirmatrelvir-ritonavir significantly reduces severe COVID-19 outcomes in diverse Taiwanese populations: Comprehensive evidence from a large-scale longitudinal cohort study in Taiwan

Nirmatrelvir-ritonavir significantly reduces severe COVID-19 outcomes in diverse Taiwanese populations: Comprehensive evidence from a large-scale longitudinal cohort study in Taiwan

Background: Nirmatrelvir-Ritonavir (NR) has proven effective for mild to moderate COVID-19 patients at risk of disease progression. Following its emergency use authorization in Taiwan in January 2022, this study aims to evaluate its impact on severe COVID-19 outcomes across different patient demogra...

Full description

Saved in:
Bibliographic Details
Main Authors: Fu-Der Wang, Yu-Hui Chang, Han-Chuan Chuang, Tsong-Yih Ou, Mei-Hui Lee, Phung-Anh Nguyen, Thanh Phuc Phan, Whitney Burton, Thi Kim Hien Nguyen, Min-Huei Hsu, Shiue-Ming Lin, Chieh Yang, Jason C. Hsu
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Journal of Infection and Public Health
Subjects:
Nirmatrelvir-Ritonavir
COVID-19
Taiwan
real-world evidence
effectiveness
outcome
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034125001091
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1876034125001091

Similar Items